02Oct/18
The World’s First-and-Only Bispecific T Cell Engager Immunotherapy Approved in Japan
Amgen, the United States biotechnology giant, recently announced that the Ministry of Health, Labor and Welfare (MHLW) has approved bispecific T cell engager immunotherapy Blincyto® (blinatumomab) for the treatment of relapsed orRead More…